The administration of dorzagliatin showed a substantial reduction in PI3K inhibitors-induced hyperglycemia compared to the control groups at 0.5 and 1.5 h (p < 0.01, Figure 5E–G and p < 0.05, Figure 5H–J). The gene discussed is PIK3CA; the disease is Hyperglycemia.